Oncocyte Corporation Hosting Business Update Call
06 déc. 2021 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
Oncocyte to Present New Data on DetermaIO Clinical Test for Immunotherapy Response in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium 2021
02 déc. 2021 08h00 HE
|
Oncocyte Corporation
Spotlight poster presentation indicates DetermaIO assay and algorithm is robust across multiple diagnostic platforms, confirms that test predicts response to immunotherapy (atezolizumab) benefit ...
Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update
09 nov. 2021 16h05 HE
|
Oncocyte Corporation
Clinical launch of DetermaIO as first and only immunotherapy response prediction clinical test that comprehensively assesses the tumor microenvironment and consistently outperforms PD-L1 IHC and other...
Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test
04 nov. 2021 08h00 HE
|
Oncocyte Corporation
DetermaIO is the first and only immunotherapy clinical test that comprehensively assesses the tumor microenvironment In clinical studies to date across multiple tissue types, DetermaIO has...
Oncocyte Strengthens Transplant Intellectual Property Portfolio with US Patent Covering Digital PCR Technology for Early Detection of Organ Transplant Rejection
27 oct. 2021 08h00 HE
|
Oncocyte Corporation
U.S. patent builds upon prior EU patent protection enabling launch of Therasure Transplant Monitor LDT and FDA kits in both the U.S. and Europe Oncocyte’s recently acquired Therasure Transplant...
Oncocyte to Report Third Quarter 2021 Financial Results on Tuesday, November 9th
26 oct. 2021 16h05 HE
|
Oncocyte Corporation
IRVINE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer
07 oct. 2021 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
Oncocyte Publishes Study Demonstrating Predictive Potential for DetermaIO® Test in Triple Negative Breast Cancer
30 sept. 2021 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
Oncocyte Announces Oral Presentation of New Data on Its DetermaIO™ Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting
20 sept. 2021 11h35 HE
|
Oncocyte Corporation
Randomized clinical trial data from NeoTRIPaPDL1 study establishes DetermaIO as a predictive biomarker of immunotherapy response Trial Investigators found DetermaIO outperformed 80 other immune...
Oncocyte Hosting Two-Part Key Opinion Leader Event Series
20 sept. 2021 08h00 HE
|
Oncocyte Corporation
Part 1: Transplant Rejection Testing – Wednesday, September 22nd @ 1pmET Part 2: DetermaIO™ in Triple-Negative Breast Cancer – Tuesday, September 28th @ 1pmET IRVINE, Calif., Sept. 20, 2021 (GLOBE...